Hutchison Medipharma Limited

Quick facts

Phase 3 pipeline

• HMPL-306 · Oncology
  HMPL-306 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.
• HMPL-523 · Oncology
  HMPL-523 is a selective inhibitor of focal adhesion kinase (FAK) that disrupts tumor cell adhesion and migration signaling.
• Savolitinib + Osimertinib · Oncology
  Savolitinib and osimertinib together target MET and EGFR pathways to overcome resistance in lung cancer.
• Surufatinib plus Toripalimab · Oncology
  Surufatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET) to block tumor angiogenesis and growth, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses.

Phase 2 pipeline

• HMPL-004 high dose
• HMPL-004 low dose
• Volitinib · Other

Phase 1 pipeline

• [14C]Sulfatinib
• epitinib succinate
• HMPL-011 capsules
• HMPL-011 tablets
• HMPL-653
• Savolitinib Reference Preparation
• Savolitinib Test Preparation
• Sulfatinib R capsule
• Sulfatinib T capsule

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Hutchison Medipharma Limited portfolio CI brief
• Hutchison Medipharma Limited pipeline updates RSS